JPMorgan Chase & Co. Has $13.85 Million Holdings in Pediatrix Medical Group, Inc. $MD

JPMorgan Chase & Co. raised its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 20.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 827,075 shares of the company’s stock after buying an additional 140,577 shares during the quarter. JPMorgan Chase & Co. owned 0.95% of Pediatrix Medical Group worth $13,854,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Smartleaf Asset Management LLC lifted its position in shares of Pediatrix Medical Group by 10.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 6,250 shares of the company’s stock valued at $101,000 after acquiring an additional 601 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Pediatrix Medical Group by 4.5% in the third quarter. PNC Financial Services Group Inc. now owns 14,525 shares of the company’s stock valued at $243,000 after purchasing an additional 631 shares in the last quarter. Amalgamated Bank boosted its position in shares of Pediatrix Medical Group by 3.5% in the third quarter. Amalgamated Bank now owns 24,891 shares of the company’s stock worth $417,000 after buying an additional 831 shares during the period. New York State Common Retirement Fund boosted its position in shares of Pediatrix Medical Group by 1.7% in the second quarter. New York State Common Retirement Fund now owns 62,245 shares of the company’s stock worth $893,000 after buying an additional 1,034 shares during the period. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of Pediatrix Medical Group by 10.0% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 11,977 shares of the company’s stock valued at $201,000 after buying an additional 1,092 shares in the last quarter. 97.71% of the stock is owned by hedge funds and other institutional investors.

Pediatrix Medical Group Price Performance

Shares of MD opened at $19.83 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.66 and a current ratio of 1.66. The firm has a market cap of $1.65 billion, a PE ratio of 10.22 and a beta of 0.79. The firm’s 50 day moving average price is $21.21 and its 200 day moving average price is $19.88. Pediatrix Medical Group, Inc. has a twelve month low of $11.84 and a twelve month high of $24.99.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Thursday, February 19th. The company reported $0.50 EPS for the quarter, missing the consensus estimate of $0.53 by ($0.03). The business had revenue of $493.77 million during the quarter, compared to the consensus estimate of $486.23 million. Pediatrix Medical Group had a return on equity of 19.59% and a net margin of 8.64%.The business’s revenue was down 1.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.51 earnings per share. As a group, research analysts expect that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

Insider Buying and Selling

In other Pediatrix Medical Group news, CEO Mark S. Ordan sold 23,000 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $22.41, for a total transaction of $515,430.00. Following the transaction, the chief executive officer directly owned 302,805 shares of the company’s stock, valued at $6,785,860.05. This represents a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MD. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on Pediatrix Medical Group in a research note on Friday, February 20th. Zacks Research lowered shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 23rd. UBS Group lowered their price objective on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 24th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th. Finally, Truist Financial decreased their target price on shares of Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating for the company in a research note on Thursday, February 19th. One equities research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $19.80.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.